Header Logo

Connection

NAOTO T UENO to Disease-Free Survival

Back to Details
This is a "connection" page, showing publications NAOTO T UENO has written about Disease-Free Survival.
NAOTO T UENO
Connection Strength
1.180
Disease-Free Survival
  1. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. PLoS One. 2021; 16(4):e0250057.
    View in: PubMed
    Score: 0.084
  2. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919.
    View in: PubMed
    Score: 0.077
  3. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213.
    View in: PubMed
    Score: 0.070
  4. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67.
    View in: PubMed
    Score: 0.064
  5. Impact of clinical trial on survival outcomes. Breast Cancer Res Treat. 2016 Sep; 159(2):273-81.
    View in: PubMed
    Score: 0.061
  6. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol. 2014 Feb; 25(2):384-91.
    View in: PubMed
    Score: 0.051
  7. Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(2):523-31.
    View in: PubMed
    Score: 0.047
  8. Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. Oncologist. 2011; 16(7):956-65.
    View in: PubMed
    Score: 0.043
  9. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Apr; 17(2):96-104.
    View in: PubMed
    Score: 0.043
  10. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011; 16(6):772-82.
    View in: PubMed
    Score: 0.042
  11. Serum HER2 levels determined by two methods in patients with metastatic breast cancer. Int J Clin Oncol. 2012 Feb; 17(1):55-62.
    View in: PubMed
    Score: 0.042
  12. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug; 51(8):1213-8.
    View in: PubMed
    Score: 0.040
  13. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010 Feb 16; 102(4):651-7.
    View in: PubMed
    Score: 0.039
  14. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008 Mar; 41(6):537-45.
    View in: PubMed
    Score: 0.033
  15. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant. 2006 May; 37(10):929-35.
    View in: PubMed
    Score: 0.030
  16. Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Res. 2020 03 15; 80(6):1304-1315.
    View in: PubMed
    Score: 0.019
  17. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.017
  18. Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. Cancer Med. 2017 Nov; 6(11):2515-2522.
    View in: PubMed
    Score: 0.017
  19. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer. 2017 Jul 01; 123(13):2422-2431.
    View in: PubMed
    Score: 0.016
  20. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997; 40(4):321-9.
    View in: PubMed
    Score: 0.016
  21. Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016 Sep; 159(2):367-74.
    View in: PubMed
    Score: 0.015
  22. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. J Natl Cancer Inst. 2016 08; 108(8).
    View in: PubMed
    Score: 0.015
  23. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist. 2016 Jan; 21(1):21-7.
    View in: PubMed
    Score: 0.015
  24. Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.014
  25. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015 Dec 15; 121(24):4324-32.
    View in: PubMed
    Score: 0.014
  26. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol. 2015 Jun; 38(3):242-7.
    View in: PubMed
    Score: 0.014
  27. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. Plast Reconstr Surg. 2015 Feb; 135(2):262e-269e.
    View in: PubMed
    Score: 0.014
  28. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015 Mar; 113(3):593-8.
    View in: PubMed
    Score: 0.013
  29. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res. 2014 Sep 16; 16(5):440.
    View in: PubMed
    Score: 0.013
  30. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res. 2014 Jul 23; 33:58.
    View in: PubMed
    Score: 0.013
  31. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med. 2014 Jul; 3(7):849-56.
    View in: PubMed
    Score: 0.013
  32. Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer. 2014 May 01; 120(9):1319-28.
    View in: PubMed
    Score: 0.013
  33. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65.
    View in: PubMed
    Score: 0.013
  34. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013 Aug; 48(8):1056-64.
    View in: PubMed
    Score: 0.012
  35. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012 Nov; 11(11):2526-34.
    View in: PubMed
    Score: 0.012
  36. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer. 2012 Aug; 12(4):264-9.
    View in: PubMed
    Score: 0.011
  37. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8.
    View in: PubMed
    Score: 0.011
  38. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. Cancer. 2012 Apr 15; 118(8):2039-47.
    View in: PubMed
    Score: 0.011
  39. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011 Aug 20; 29(24):3214-23.
    View in: PubMed
    Score: 0.011
  40. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
    View in: PubMed
    Score: 0.011
  41. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. Oncologist. 2011; 16(2):155-64.
    View in: PubMed
    Score: 0.010
  42. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64.
    View in: PubMed
    Score: 0.008
  43. Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Oct 01; 110(7):1436-44.
    View in: PubMed
    Score: 0.008
  44. Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2008 Jan-Feb; 18(1):80-4.
    View in: PubMed
    Score: 0.008
  45. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14.
    View in: PubMed
    Score: 0.007
  46. The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004 Nov; 10(11):794-804.
    View in: PubMed
    Score: 0.007
  47. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.
    View in: PubMed
    Score: 0.006
  48. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant. 2002 May; 29(10):861-6.
    View in: PubMed
    Score: 0.006
  49. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12.
    View in: PubMed
    Score: 0.005
  50. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.